Mergers & Acquisitions
Clario Acquires WCG's Neuro-Focused eCOA Business
Fierce Biotech
•
March 12, 2025
Clario has acquired WCG's neurology-focused electronic clinical outcome assessment (eCOA) business. This acquisition strengthens Clario's position in decentralized clinical trials and enhances its technology offerings for neurological studies.
Clario's acquisition of WCG's neurology-focused eCOA business reflects the increasing adoption of decentralized clinical trials and the growing demand for advanced technologies in data collection and analysis. eCOA technologies streamline the clinical trial process, improving efficiency and patient engagement. By integrating WCG's specialized eCOA expertise, Clario expands its capacity to conduct high-quality neurological studies. This acquisition signals a significant step forward in the use of technology within clinical trials and its potential to improve the development of new treatments for neurological disorders.